Artiva Biotherapeutics (NASDAQ:ARTV) Director Buys $4,339,267.80 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 548,580 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was purchased at an average price of $7.91 per share, with a total value of $4,339,267.80. Following the transaction, the director owned 16,231,717 shares of the company’s stock, valued at approximately $128,392,881.47. This represents a 3.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock traded up $0.58 during trading on Thursday, reaching $8.00. The company had a trading volume of 1,059,213 shares, compared to its average volume of 488,136. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $14.53. The stock’s 50 day moving average price is $8.89 and its two-hundred day moving average price is $6.12.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Sell-side analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ARTV shares. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday. Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the business. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $41,000. Bank of America Corp DE raised its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Artiva Biotherapeutics in the first quarter worth $131,000. OMERS ADMINISTRATION Corp acquired a new stake in Artiva Biotherapeutics in the fourth quarter worth $91,000. Finally, Sanctuary Advisors LLC acquired a new stake in Artiva Biotherapeutics in the first quarter worth $139,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.